Lanham O'Dell & Company, Inc. Ocugen, Inc. Call Options Transaction History
Lanham O'Dell & Company, Inc.
- $165 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCGN
# of Institutions
117Shares Held
75MCall Options Held
200KPut Options Held
151K-
Black Rock Inc. New York, NY17.9MShares$12.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.7MShares$11.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$4.89 Million0.0% of portfolio
-
State Street Corp Boston, MA5.93MShares$4.21 Million0.0% of portfolio
-
Ubs Group Ag4.37MShares$3.1 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $154M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...